Valuation
- Market cap
- 590,883,000
- Revenue TTM
- $0
- Net income TTM
- $-60,555,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 169,300
- Avg volume
- —
- Day's range
- $18.27 – $19.86
- Shares out
- 31,785,000
- Stochastic %K
- 16%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $35.40
Company profile
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refra...
Show more
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (858) 732-3880
- Website
- https://bhtherapeutics.com
- Address
- 10255 Science Center Drive, Suite 200, San Diego, United States
Latest news
No headlines yet.
